Title |
Rituximab for relapsing-remitting multiple sclerosis
|
---|---|
Published by |
John Wiley & Sons, Ltd, December 2011
|
DOI | 10.1002/14651858.cd009130.pub2 |
Pubmed ID | |
Authors |
He, Dian, Zhou, Hongyu, Han, Wenjie, Zhang, Shihong |
Abstract |
More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course. Approximately ten years after disease onset, an estimated 50% of individuals with relapsing-remitting MS (RR-MS) convert to secondary progressive MS. Quality of life is considerably impaired in early RR-MS. The increased costs are associated with relapse occurrence and increasing disease severity. Pharmaceutical interventions aimed at delaying the progression of disease may help to reduce the economic burden of MS. It has been showed that B lymphocytes involve in the pathophysiology of MS and rituximab lyses B cells via complement and antibody-dependent cellular cytotoxicity. Current clinical trials are evaluating the role of rituximab as a B-cell-targeted therapy in the treatment of RR-MS. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 8% |
Spain | 1 | 4% |
Singapore | 1 | 4% |
Switzerland | 1 | 4% |
Unknown | 20 | 80% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 28% |
Professor > Associate Professor | 3 | 12% |
Professor | 2 | 8% |
Student > Postgraduate | 2 | 8% |
Student > Ph. D. Student | 2 | 8% |
Other | 4 | 16% |
Unknown | 5 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 44% |
Agricultural and Biological Sciences | 3 | 12% |
Neuroscience | 2 | 8% |
Business, Management and Accounting | 1 | 4% |
Unknown | 8 | 32% |